Skip to main content
Unique Neoantigens Arise from Somatic Mutations in Patients with Gastrointestinal Cancers.
Cancer Discov
  • Maria R Parkhurst
  • Paul F Robbins
  • Eric Tran, Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, Oregon
  • Todd D Prickett
  • Jared J Gartner
  • Li Jia
  • Gabriel Ivey
  • Yong F Li
  • Mona El-Gamil
  • Almin Lalani
  • Jessica S Crystal
  • Abraham Sachs
  • Eric Groh
  • Satyajit Ray
  • Lien T Ngo
  • Scott Kivitz
  • Anna Pasetto
  • Rami Yossef
  • Frank J Lowery
  • Stephanie L Goff
  • Winifred Lo
  • Gal Cafri
  • Drew C Deniger
  • Parisa Malekzadeh
  • Mojgan Ahmadzadeh
  • John R Wunderlich
  • Robert P T Somerville
  • Steven A Rosenberg
Document Type
Publication Date

Immunotherapies can mediate regression of human tumors with high mutation rates, but responses are rarely observed in patients with common epithelial cancers. This raises the question of whether patients with these common cancers harbor T lymphocytes that recognize mutant proteins expressed by autologous tumors that may represent ideal targets for immunotherapy. Using high-throughput immunologic screening of mutant gene products identified via whole-exome sequencing, we identified neoantigen-reactive tumor-infiltrating lymphocytes (TIL) from 62 of 75 (83%) patients with common gastrointestinal cancers. In total, 124 neoantigen-reactive TIL populations were identified, and all but one of the neoantigenic determinants were unique. The results of

Clinical Institute
Clinical Institute
Digestive Health
Earle A. Chiles Research Institute
Citation Information
Maria R Parkhurst, Paul F Robbins, Eric Tran, Todd D Prickett, et al.. "Unique Neoantigens Arise from Somatic Mutations in Patients with Gastrointestinal Cancers." Cancer Discov (2019)
Available at: